COVID-19: Medicago develops vaccine: Plant-derived MT-2766
COVID-19: Vaccine
Mitsubishi Tanabe Pharma: Medicago
Medicago, a consolidated subsidiary, aims to prevent COVID-19 with the Government of Canada.
Developed a plant-derived virus-like particle VLP vaccine (development number: MT-2766).
Government of Canada:
“Contract to receive a subsidy of 173 million Canadian dollars (about 13.7 billion yen)” from the Canadian government
“Contract to supply up to 76 million vaccines” to the Government of Canada
We will inform you that it has been concluded.
MT-2766 clinical trial:
Medicago is currently conducting a clinical trial of MT-2766 in Canada.
Phase 1 clinical trials will be completed shortly.
In addition, in order to evaluate the safety and efficacy of this vaccine,
Phase 2 clinical trials from November
Phase 3 clinical trials from December
I plan to start.
Nihon Keizai Shimbun
https://www.nikkei.com/article/DGXLRSP542288_W0A021C2000000/
Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine.
PrimeMinister announces funding to advance the development of Canadian COVID-19 vaccine technologies